Treatment with 7-O-tetradecanoyl-genistein reduces IFN-γ and IL-17 levels in the brain and ameliorates clinical signs of experimental autoimmune encephalomyelitis

摘要

Experimental autoimmune encephalomyelitis (EAE) is a murine autoimmune disease used to study multiple sclerosis (MS), a human inflammatory demyelinating disease of the central nervous system. Genistein treatment is known to reverse clinical signs of EAE. The present work investigates the use of a genistein analog 7-. O-tetradecanoyl-genistein (TDG) in the treatment of EAE. In this study, the genistein analog TDG was obtained by the esterification reaction of genistein. The molecule of TDG was developed based on this previous knowledge, using esterification in vitro to bypass the in vivo processing which favors the biological activity and increasing lipid solubility. The results show that TDG treatment promotes reduction of the clinical signs in EAE animals and it correlates with lower levels of TGF-β, IL-6, IL-17 and IFN-γ in the brain.